Information:
Error:
ID
27801
Description
RATIONALE: Nilotinib and imatinib m esylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Concomitant Therapy Form.
Keywords
Versions (1)
- 11/29/17 11/29/17 -
Copyright Holder
Gruppo Italiano Malattie EMatologiche dell'Adulto
Uploaded on
November 29, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Concomitant Therapy GIMEMA CML0408 NCT00769327
Similar models
Concomitant Therapy
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Concomitant pharmacological therapies
C1707479 (UMLS CUI-1)
Acronym
Item
Acronym
integer
C2986333 (UMLS CUI [1])
Start date of administration
Item
Start date of administration
date
C2826734 (UMLS CUI [1])
End date of administration
Item
End date of administration
date
C2826744 (UMLS CUI [1])
Drug
Item
Drug
text
C0013227 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,2])